Research
Hormonal
Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.
Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.
StrongSupportsmedium confidence
Over a lifetime, tirzepatide would avert 45 609 obesity cases (95% uncertainty interval [UI], 45 092-46 126) per 100 000 individuals.
Why this rating
Based on a lifetime cost-effectiveness analysis using a validated model.
Source
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Jennifer H. Hwang et al. · JAMA Health Forum · 2025
DOI 10.1001/jamahealthforum.2024.5586
other · n=4823Cited 50×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →